Dividend Win Wednesday: Semiconductor Capital at 90% Drawdown and the Oncology M&A Wave

This Week's Setup

Energy and semiconductor capital equipment anchor the dividend board after last week's rotation, while biotech picks up three slots with insider activity in every name. KLA Corporation sits at Pixie Rank 2 with a 13.5% FCF yield at an 89.7% drawdown from the 52-week high, the deepest dip on the screen and nearly nine times the energy names that surround it.

The S&P 500 CAPE at 38.9 remains in the top decile of historical observations; Fear & Greed at 42 marks the second consecutive week below 50, and the VIX at 15.9 sits below its long-run average. Gold miners, pharma, and steel are all present with double-digit drawdowns and payout ratios below 50%.

Quick Scan

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 3.2% | Payout ratio: 51.3% | 52w drawdown: -22.2%

ConocoPhillips holds the top Pixie Rank with a 5.6% FCF yield and an earnings yield of 5.6%, 5.0 percentage points above the 10-year normalized level; the 17.96 P/E sits below the broad market multiple and reflects the sector's cyclical discount despite revenue growing 7.7% year over year.

Three insiders filed Form 4 transactions between June 22 and July, including Mejia Cardona Andres Felipe, Vatnick Silvina, and Escovar Gomez Sylvia; no dollar amounts are disclosed in the filings, but the cluster timing aligns with the 22% drawdown from the 52-week peak.

Truist cut the price target to $115 from $128 on July 8, a 7.7% reduction that narrows the implied upside to 35.0% from the current $105.77 price; the company reports earnings August 6 with an estimated EPS of $2.84 and revenue of $19.2 billion.

2. KLA Corporation (KLAC)

Dividend yield: 4.3% | Payout ratio: 29.6% | 52w drawdown: -89.7%

KLA delivers a 13.5% FCF yield at an 89.7% drawdown, the steepest decline on the screen and a signal that the semiconductor capital equipment selloff has created a valuation gap; the 6.02 P/E and 66.5% ROIC frame the dislocation, with revenue up 23.9% year over year and gross margin at 60.9%.

Higgins Bren D. filed two insider transactions on July 2 and July 6, and WALLACE RICHARD P filed on June 11; the buying follows the drawdown into territory the stock has not visited since 2023, and the next earnings date is July 28 with an estimated EPS of $1.00 and revenue of $3.6 billion.

Analyst targets imply 772.8% upside to $1,855.14, a forecast that embeds a full recovery to pre-drawdown multiples and assumes the AI-driven inspection and metrology cycle extends without interruption; any softness in TSMC or Samsung capital spending would compress that target materially.

3. Newmont Corporation (NEM)

Dividend yield: 1.1% | Payout ratio: 15.7% | 52w drawdown: -29.7%

Newmont posts a 7.2% FCF yield and an 8.1% earnings yield at a 29.7% drawdown, with revenue growth of 21.3% year over year and a 53.2% gross margin; the 12.29 P/E and 29.8% ROIC position the company as the highest-return gold miner on the board, and net debt to EBITDA sits at -0.20, meaning the balance sheet is net cash.

The 1.1% dividend yield is the lowest in the top eight, and the payout ratio of 15.7% reflects a reinvestment-heavy capital allocation policy rather than a yield-focused return strategy; investors looking for income will find better nominal yields elsewhere on the screen.

Toth Peter filed an insider transaction on July 6; the net insider activity over six months shows 18,394 shares sold with zero buys, a pattern that offsets the recent single purchase and suggests senior management is taking profits near the current price.

4. Novartis AG (NVS)

Dividend yield: 3.0% | Payout ratio: 64.7% | 52w drawdown: -7.9%

Novartis delivers a 3.0% dividend yield with a 5.1% FCF yield and a 76% gross margin, the highest on the screen; revenue growth of 9.6% year over year and a 22.50 P/E frame the pharma giant as a stable cash generator at a shallow 7.9% drawdown, and the 64.7% payout ratio leaves room for dividend growth at the 7.2% five-year CAGR.

Novartis announced the acquisition of Myricx Bio in a $1.5 billion oncology deal on July 8, adding a clinical-stage asset pipeline to the existing franchise; the move follows Jim Cramer's July 8 statement that biotech is "the hottest group in the market" and predicts "deals are going to be flooding the market," positioning Novartis as a consolidator in the M&A wave.

Analyst targets imply -2.0% downside to $153.87 from the current $157.02 price, a rare inversion that signals the Street expects margin compression or pipeline delays; the company reports earnings July 21 with an estimated EPS of $2.15 and revenue of $14.1 billion.

5. EOG Resources, Inc. (EOG)

Dividend yield: 3.1% | Payout ratio: 43.6% | 52w drawdown: -12.9%

EOG Resources holds a 4.9% FCF yield and a 7.7% earnings yield at a 12.9% drawdown, with a 63.4% gross margin and a 13.02 P/E; the 15.2% ROIC and 3.5% shareholder yield combine with the 43.6% payout ratio to frame the company as a disciplined capital allocator in the independent oil space.

Revenue declined 3.4% year over year, the only negative growth figure in the top five names, and the drawdown is shallow relative to peers like ConocoPhillips; the yield spread of 3.2 percentage points above the 10-year normalized earnings yield reflects the sector's structural discount but does not compensate for the revenue decline.

Donaldson Michael P, Janssen Ann D., and Yacob Ezra Y each filed insider transactions on July 2; the six-month net insider activity shows 14,343 shares sold with zero buys, a pattern that undercuts the recent filing cluster and suggests the July transactions are not a conviction signal.